Does tesamorelin raise IGF-1?

What the research literature says

Tesamorelin acts upstream of the GH axis at the GHRH receptor on pituitary somatotrophs. Receptor engagement triggers pulsatile GH release; circulating GH then engages the growth hormone receptor on hepatocytes, driving hepatic IGF-1 synthesis and release into circulation. Serum IGF-1 thus serves as the downstream biomarker quantifying whether the GHRH-receptor engagement at the pituitary translated into peripheral-tissue signalling.

The Falutz NEJM trial in HIV-associated lipodystrophy patients documented IGF-1 elevation alongside the primary visceral-adipose-tissue reduction endpoint (PMID 18057338). The Falutz pooled phase 3 analysis consolidated IGF-1 dynamics across two multicentre placebo-controlled trials with safety-extension data (PMID 20554713). IGF-1 elevation is treated as a target-engagement confirmation rather than as a direct efficacy endpoint — the integrated tissue-level metabolic effects observed in the trials reflect cumulative GH and IGF-1 axis activity over weeks of daily dosing.

The Spooner pharmacotherapy review covers IGF-1 monitoring as part of the clinical-pharmacology framework (PMID 22298602), with serum IGF-1 measurements supporting both target-engagement verification and safety monitoring across treatment protocols.

Why this matters in research context

Researchers studying GHRH-axis pharmacology with tesamorelin should expect to see IGF-1 elevation as the canonical pharmacodynamic readout. The magnitude and time course of IGF-1 response varies across individuals and depends on dose, dosing interval, baseline GH-axis status, and downstream IGF-1 system regulation. Steady-state IGF-1 elevation is typically established within the first week of once-daily dosing.

Related compounds

• Tesamorelin 10mg — the compound covered by this answer
• CJC-1295 No DAC 10mg — alternative GHRH analogue with shorter half-life
• Ipamorelin 10mg — complementary GHSR-1a agonist; pairs with GHRH analogues in dual-receptor protocols

Related research questions

• What is the half-life of tesamorelin?
• Is tesamorelin FDA approved?
• Does ipamorelin raise cortisol?

References

1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
2. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304. [PMID 20554713]
3. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012;46(2):240-247. [PMID 22298602]